1 / 38

Review of Antibiotics

Review of Antibiotics. Zagorka Popovski, Pharm.D. Clinical Pharmacist, Intensive Care. Cephalosporins. Gram + 1 st Generation •Ancef •Keflex . LESS IS MORE!!!. Timing of pre op antibiotic is key. POPOVSKI and TEOH SCCM 1993 SAN DIEGO CA.

keiji
Download Presentation

Review of Antibiotics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Review of Antibiotics Zagorka Popovski, Pharm.D. Clinical Pharmacist, Intensive Care

  2. Cephalosporins Gram + 1st Generation •Ancef •Keflex

  3. LESS IS MORE!!! • Timing of pre op antibiotic is key

  4. POPOVSKI and TEOHSCCM 1993 SAN DIEGO CA • REDUCTION OF POST-OP ANTIBIOTICS FROM 72 HR TO 48HR • ADMINISTER PRE-OP ANTIBIOTIC IN OR • WOUND INFECTION RATE REDUCED FROM 2% TO 0.6%

  5. Cephalosporins Gram + Gram + Coverage plus: 1st Generation •Ecoli •Ancef •Proteus •Keflex •Klebsiella

  6. Cephalosporins Gram + 1st Generation 2nd Generation •Ancef •Cefuroxime •Keflex •Cefamandole •Cefotetan +/- anaerobe •Cefoxitin H Flu

  7. Cephalosporins Gram + Gram - 1st Generation 2nd Generation 3rd Generation •Ancef •Cefuroxime •Ceftriaxone •Keflex •Cefamandole •Cefotaxime •Cefotetan •Ceftazidime •Cefoxitin

  8. Cephalosporins Gram - Gram - Coverage *3rd Generation Acinetobacter Serratia •Ceftriaxone (CNS penetration, gram neg. alternative to amnioglycosides) •Cefotaxime •Ceftazidime •Pseudomonas Aeruginosa *not for enterobacter

  9. Penicillins ® Penicillin Ampicillin Cloxacillin Amoxillin Oxacillin Nafcillin Methicillin

  10. Penicillins Coverage •Ampicillin •Enterococcus •Amoxicillin •Ecoli •Klebsiella •Proteus •H. Flu Clavulin®=amoxicillin+clavulinic acid

  11. Antipseudomonal Penicillins • Piperacillin (Pipracil) • Piperacillin/Tazobactam (Tazocin) • Ticarcillin (Ticar) • Ticarcillin/Clavulante (Timentin) Gram +/- (including Pseudomonas a.) *anaerobic coverage

  12. + R R

  13. Penicillins • Cloxacillin • Oxacillin • Nafcillin • Methicillin

  14. Carbapenems • Imipenem + Cilastatin (Primaxin) • Meropenem (Merrem) • Ertapenem (Invanz)

  15. Meropenem • Very broad spectrum • Gram negative including pseudomonas • gram positive including staph and enterococcus • Anaerobes • Indicated for “high-severity” intra-abdominal infections • Replaced imipenem//cilastatin at HHS

  16. Christou & Solomkin, 1990 (Intra-abdominal sepsis) F A I L U R E AA + AMG Imipenem 5 7 15 30 A.P.A.C.H.E.

  17. Activity of Study Agents Against Facultative Gram-Negative Bacteria

  18. Activity of Study Agents Against Common Anaerobic Bacteria

  19. CONDITIONS FOR WHICH THERAPEUTIC ANTIBIOTICS (24h) ARE NOT RECOMMENDED • Traumatic and iatrogenic enteric perf’n operated on within 12h • Gastroduodenal perf’n operated on within 24h • Acute/gangrenous appendicitis without perf’n • Acute/gangrenous cholecyswtitis without perf’n • Transmural bowel necrosis from embolic,thrombotic or obsstructive vascular occlusion without perf’n or established peritonitis or abcess

  20. Fluoroquinolones • Nalidixic acid (NegGram) • Ciprofloxacin (Cipro) • Norfloxacin (Noroxin) • Levofloxacin (Levaquin) • Gatifloxacin (Tequin) • Moxifloxacin (Avelox)

  21. Fluoroquinolones • Ciprofloxacin (Cipro) - Ps. a. • Norfloxacin (Noroxin) • Levofloxacin (Levaquin) • Gatifloxacin (Tequin) • Moxifloxacin (Avelox) CAP Strep. + other gram neg atypicals

  22. Fluoroquinolones • Advantages (Bioavailability, IV/PO, tissue penetration) • Drug Interactions (Calcium, Iron, Magnesium) (Theophylline,Methylxanthines) • Side Effects

  23. Aminoglycosides • Gentamicin • Tobramycin • Amikacin

  24. Aminoglycosides MIC Serratia (Pseudomonas a.) Gentamicin .5 2 Tobramycin 2 .5

  25. Others • Vancomycin • Linezolid • Septra

  26. SAVING ANTIBIOTICS SAVES LIVES!!! PRINCIPLES: • For empiric therapy, reassess at day 4, consult ID • Narrow spectrum when bacteria identified • Convert to oral therapy when possible

  27. SAVING ANTIBIOTICS SAVES LIVES!!! • Clinical Pulmonary Infection Score (CPIS) • Takes into account temperature,wbc,secretions,ventilation,xray • </- 6 ( treat with 3 days levofloxacin or cefotaxime) • >6 ( bronch and treat with 8 days

  28. SAVING ANTIBIOTICS SAVES LIVES!!! • BENEFITS: • Reduced use of broad spectrum agents • Reduced resistance • Reduced LOS • Reduced fungal infections • Reduced costs >$200,000

  29. CPIS Use for Non-invasive Diagnosis of HAP/VAP Calculate CPIS CPIS≤6 CPIS>6 Consider treatment Gram stain of Tracheobronchial (TB) secretions Recalculate CPIS daily, examine Gram stain Treatment according to Gram stain Pugin J. Am Rev Respir Dis. 1991;143:1121-9. Pugin J. Minerva Anestesiol. 2002;68(4):261-5. 1 2 3 4 5 6 7 Back Next

  30. CPIS Antibiotic Study • Inclusion Criteria: • Clinical Pulmonary infection score (CPIS) 6 • Ventilated or non-ventilated • Exclusion Criteria: • Infected with HIV • 18 years of age Singh N, et al. Am J Respir Crit Care Med. 2000;162:505-511. 1 2 3 4 5 6 7 Back Next

  31. CPIS Antibiotic Study: Trial Design CPIS≤6 Standard Therapy (antibiotics for 10-21 days) Experimental Therapy Ciprofloxacin for 3 days CPIS calculated at 3 days CPIS ≤6 CPIS >6 Discontinue treatment Treat as pneumonia Singh N, et al. Am J Respir Crit Care Med. 2000;162:505-11. 1 2 3 4 5 6 7 Back Next

  32. CPIS Antibiotic Study: Outcomes • Data for patients with entry CPIS 6 subject to standard and experimental therapy Singh N, et al. Am J Respir Crit Care Med. 2000;162:505-511. 1 2 3 4 5 6 7 Back Next

  33. CPIS Antibiotic Study: Outcomes • Data for patients with CPIS 6 at the 3-day evaluation point and no extrapulmonary infections Singh N, et al. Am J Respir Crit Care Med. 2000;162:505-511. 1 2 3 4 5 6 7 Back Next

  34. CPIS Antibiotic Study: Conclusions • Prolonged (i.e. >3 days) use of antibiotics in patients with an initial CPIS ≤6 may be unnecessary and inappropriate Singh N, et al. Am J Respir Crit Care Med. 2000;162:505-511. 1 2 3 4 5 6 7 Back Next

  35. FUNGAL INFECTIONS • RISK FACTORS • TPN • Steroids • Broad spectrum antibiotics • Abdominal involvement • Immunosuppression

  36. ANTIFUNGAL AGENTS • Polyenes: Amphotericin B (binds to sterols and disrupts barrier resulting in leakage of intracellular contents • For hemodynamically unstable, systemic infections • Adverse effects may limit treatment

  37. ANTIFUNGAL AGENTS cont’d • Azoles: Fluconazole, voriconazole, itraconazole (inhibit p450-mediated 14-alpha demethylase in the sterol) • Good activity vs C. albicans, resistance to Krusei, Glabrata • Numerous drug interactions

  38. ANTIFUNGAL AGENTS cont’d • Echinocandins: Caspofungen (inhibit fungal cell wall synthesis) • Active against C. albicans, krusei, glabrata • cost

More Related